Wilmot Expert Gets $550,000 Grant from Leukemia & Lymphoma Society
July 07, 2008
The Leukemia & Lymphoma Society recently awarded a $550,000 career development grant to Jonathan Friedberg M.D., M.M.Sc.,
of the James P. Wilmot Cancer Center at the University of Rochester Medical Center to advance research of new agents for the treatment of lymphomas.
The Scholar in Clinical Research Career Development Grant, funded in part by Millennium Pharmaceuticals, the Takeda Oncology Company, is a five-year program to support Friedberg’s study of the drug R788 for patients with indolent and mantle cell non-Hodgkin lymphoma (NHL).
Friedberg has already shown in several patients that R788 is safe and effective. He is now using preclinical models to evaluate R788 in combination with other agents. Once the most promising combination is identified, Friedberg will pursue a clinical trial enrolling patients with relapsed indolent and mantle cell NHL.
“To effectively eradicate cancers we must learn which molecules cause them and then develop new treatments that kill cancer cells without harming healthy cells,” said Barton Kamen, M.D., Ph.D., chief medical officer of LLS. “Dr. Friedberg’s work shows exceptional promise and is likely to lead to improved treatments for patients with various types of lymphoma.”
Friedberg is associate professor of Medicine and director of hematological malignancies clinical research at the Wilmot Cancer Center.
The LLS Career Development Program funds talented investigators who are accomplishing cutting-edge research in established and new laboratories.